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women. The changes in expression of Gal-3 were more dra-
matic in EECs than ESCs. Moreover, estrogen (E2) and pro-
gesterone (P4) induced Gal-3 expression in EECs of healthy 
groups, and P4 was more significant than E2 and combined 
E2 and P4 (E2P4). However, in the endometriosis group, P4 
failed to induce a similar increase in Gal-3 expression.
Conclusions Our results suggest that aberrant expres-
sion of Gal-3 might contribute to infertility in patients with 
endometriosis due to progesterone resistance.
Keywords Endometriosis · Galectin-3 (Gal-3) · Uterine 
receptivity · Sex hormone
Introduction
Endometriosis is a benign gynecological disorder with 
malignant biological characteristics and is defined by the 
presence of endometrial glands and stroma outside the uter-
ine cavity. Ectopic endometrial cells can spread to pelvic 
organs such as rectum, bladder, and ovaries. This spread-
ing contributes to various clinical manifestations includ-
ing irregular uterine bleeding, dyspareunia, chronic pelvic 
pain, and infertility: a condition affecting 10 % of women 
of reproductive age [1–3]. Statistically, 30–50 % of females 
with endometriosis are infertile and 25–50 % of females 
with infertility have endometriosis [4]. Although the asso-
ciation between endometriosis and infertility has been well 
established, the underlying mechanisms remain unknown.
It has been proposed that abnormal endometrial devel-
opment in patients with endometriosis contributes to 
endometriosis-related infertility [5]. It is well known that 
endometrial receptivity is vital in women’s fertility. Human 
tissue and mouse model studies have demonstrated that the 
molecular markers of endometrial receptivity are altered 
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in both humans and mice with endometriosis. Integrins, 
matrix metalloproteinases (MMPs), and homeobox genes 
(HoxA10) display aberrant expression patterns in the 
eutopic endometrium of women with endometriosis [6, 
7]. Other alterations of biochemical or molecular markers 
have also been reported, including changes in the levels of 
vascular endothelial growth factor (VEGF) [8] and inter-
leukin 6 (IL-6) [9]. Galectin-3 (Gal-3), a β-galactoside-
binding protein, has been related to endometrial receptiv-
ity during embryonic implantation recently [10, 11]. Gal-3 
with a ~31 kDa lectin contains a collagen-α-like domain, 
an N-terminal domain, and the carbohydrate recognition 
domain (CRD) [12]. These three structures allow Gal-3 to 
possess specific biological functions, including cell adhe-
sion, migration, cell-extracellular matrix interactions [13], 
immune response, [14] and signal transduction [15]. It has 
been shown that Gal-3 is expressed in many cell types, 
including endometrial cells and trophoblast cells [16–19]. 
Previous studies have reported that Gal-3 is specifically 
expressed in endometrial cells in the secretory phase [10, 
20], in placental tissue during early pregnancy, and in 
decidua surrounding the site of implantation. Due to these 
findings, we speculated that the expression of Gal-3 might 
be aberrant in endometriosis patients with infertility.
Additionally, Gla-3 has been known as a component of 
a nuclear and cytoplasmic complex, shuttling between the 
nucleus and cytoplasm [21]. Estrogen and progesterone 
belong to the nuclear hormone superfamily transcription fac-
tors, which play important role in the formation of receptive 
endometrium. Furthermore, it has been demonstrated that 
endometriosis-related infertility is associated with abnormal 
sex hormone regulation [22]. Thus, it would be interesting to 
explore whether the expression of Gal-3 is regulated by sex 
hormones in secondary infertility of endometriosis patients.
Materials and methods
Tissue collection
We collected endometrial tissue samples from 34 women, 
aged 28–35 years (mean age 31.51 ± 3.52), who con-
sulted for infertility and were found to have surgically 
and histologically-confirmed endometriosis. As controls, 
we also collected endometrial biopsy specimens from 34 
healthy women aged 30–35 years (mean age 32.55 ± 3.90). 
Women in the control group underwent tubal sterilization 
and were laparoscopically confirmed to be free of endome-
triosis. These women displayed normal menstrual cycles 
and had not received anti-inflammatory or hormonal ther-
apy within 3 months prior to surgery. The phase of the sub-
jects’ menstrual cycle was determined according to the cri-
teria of Noyes et al. [23].
The endometrial tissue samples from each group were 
digested for cell culture, snap frozen and kept under 
−80 °C for subsequent real-time PCR and western blot 
analysis, or fixed in 4 % paraformaldehyde for paraffin 
blocks. Informed consent was obtained in writing from all 
subjects before surgery.
Cell culture
Primary proliferative phase endometrial stromal and glan-
dular epithelial cells were obtained from six subjects in the 
endometriosis group and six subjects in the control group. 
For each subject, secretory phase endometrial stromal and 
glandular epithelial cells were also obtained. Endometrial 
tissue was transported from the site of collection to the 
laboratory in Hanks’ balanced salt solution. The tissue was 
then minced and digested in Hanks’ balanced salt solution 
containing 1 % penicillin, 1 % streptomycin, 5 % colla-
genase, and 0.5 % deoxyribonuclease at 37 °C for 30 min 
with agitation. The dispersed endometrial cells were sepa-
rated by filtration through a wire sieve (73-mm diameter 
pore, Sigma). The endometrial glands (largely undispersed) 
were retained by the sieve, whereas the dispersed stromal 
cells passed through the sieve into the filtrate. Endometrial 
glandular epithelial cells (EECs) were plated on Madri-
gal coated 12 well-plates, while endometrial stromal cells 
(ESCs) were plated on plastic 12-well plates. Both types 
of cells were plated in DMEM/F12 phenol red medium 
(Gibco Invitrogen,Carlsbad, CA, USA) containing 10 % 
fetal bovine serum (FBS) (Gibco). Cell cultures were main-
tained at 37 °C in a humidified atmosphere (5 % CO2) and 
were allowed to replicate to confluence. Thereafter, cells 
were passaged by standard methods of trypsinization and 
allowed to replicate to confluence, which required approxi-
mately 24–48 h. Cells after first passage were characterized 
as described previously [24].
Real‑time PCR analysis
Total RNA was extracted from 34 samples from the endo-
metriosis group and 34 samples from the control group 
using Trizol Reagent (Invitrogen). Total RNA (1 μg) was 
reverse transcribed using a PrimeScript RT reagent kit 
(Takara, Dalian, China). Reverse-transcription PCR was 
performed prior to quantitative real-time PCR. The mRNA 
levels were determined by real-time PCR using SYBR Pre-
mix Ex Taq (TaKaRa) with the Applied Biosystems 7000 
system SDS software as previous described [25]. Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) was used as 
an endogenous control to normalize for differences in the 
amount of total RNA in each sample. The primer sequences 
and the sizes of the amplified fragments were as follows: 
Gal-3 (93 bp) 5′-CTT CCA CTT TAA CCC ACG CTT 
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CAA-3′ (sense), 5′-TGT CTT TCT TCC CTT CCC CAG 
TTA TT-3′ (anti-sense); GAPDH (131 bp) 5′-ATG ACC 
CCT TCA TTG ACC-3′ (sense), 5′-GAA GAT GGT GAT 
GGG ATT TC-3′ (anti-sense).
Immunohistochemistry
The paraffin blocks were cut into sections of 4 μm, 
mounted on polylysine-coated microslides, dewaxed, 
and rehydrated. Then, tissue sections were incubated in 
3 % hydrogen peroxide at room temperature. For antigen 
retrieval, tissue slides were immersed in citric acid and 
boiled in a microwave oven. The sections were washed 
in distilled water and phosphate buffered saline (PBS, 
Gibco), and then subjected to bovine serum to block unspe-
cific binding agents. This step was followed by overnight 
exposure (4 °C) to the mouse anti-human Gal-3 antibody 
(mab1154, R&D Systems Inc., Minneapolis, MN, USA) in 
a humidified chamber. After being rinsed in PBS, the sec-
tions were incubated with the bridging rabbit anti-mouse 
immunoglobulins conjugated with horseradish peroxidase 
(HRP)-labelled dextran polymer for 1 h. After washing in 
PBS, diaminobenizidine tetrahydrochloride (DAB) solu-
tion was applied, followed by running tap water as well as 
nuclear counterstaining with haematoxylin (Sigma, USA). 
The stained slides were viewed under microscopy (OLYM-
PUS OPTICAL CO., Ltd.) under 400× magnification. 
Positive cells were characterized by the brown staining of 
Gal-3 antibody. The intensity and distribution of the stain-
ing reaction were evaluated by two blinded, independent 
observers.
Western blot
Protein samples were extracted from tissues or cells, and 
the protein concentration was measured by bicinchoninic 
acid assay (BCA). Samples were run in SDS-PAGE gel, 
transferred to nitrocellulose membranes, and immunob-
lotted overnight with gentle shaking at 4 °C with primary 
antibodies. The primary antibodies included monoclonal 
mouse anti-human Gal-3 antibody (1:2500) and mono-
clonal mouse anti-human GAPDH (Kangchen, Shanghai, 
China) antibody (1:5000). This procedure was followed by 
incubation with horseradish peroxidase-conjugated second-
ary antibodies. The reactions were detected by enhanced 
chemiluminescence assay. GAPDH was used as an endog-
enous control for normalization.
Hormonal stimulation protocol
For the hormone stimulation test, 5 × 105 cells in 1 ml of 
media were plated on a 6-well plate and grown for 24 h in 
normal medium containing 10 % FBS without antibiotics. 
Then, the media were replaced by serum-free and phenol 
red-free culture media for 24 h to prepare for the stimula-
tion experiment. Stimulation was performed under vari-
ous concentrations of 17β-estradiol (E2, 0, 10−10–10−6 M, 
Sigma) alone and under various concentrations of pro-
gesterone (P4, 0, 10−9–10−5 M, Sigma) alone. The same 
experiment was performed with E2, P4, or E2 combined 
with P4 (E2P4, 10−8 M E2, 10−7 M P4, Sigma) for 24, 48, 
and 72 h. The control was plated in phenol red-free culture 
media containing charcoal-stripped 10 % FBS (Bioind, 
Shanghai, China).
Statistical analysis
Data were expressed in terms of mean ± SEM. One-way 
ANOVA analyses were performed and least significant dif-
ference (LSD) tests were applied for post hoc testing using 
SPSS software version 15.0 with p < 0.05 considered statis-
tically significant.
Results
Gal‑3 expression in endometria of endometriosis 
and control groups
To verify whether expression of Gal-3 is abnormal in the 
endometria of the endometriosis group, we performed 
immunochemistry analysis to display the expression pat-
tern of Gal-3 proteins in endometria from both the healthy 
and endometriosis group (Fig. 1). Our results showed that 
Gal-3 was presented in the endometrium from both the con-
trol group (Fig. 1b) and the endometriosis group (Fig. 1c).
Then, Gal-3 mRNA expression levels in all endome-
trium samples were detected by real-time PCR analysis. As 
shown in Fig. 2a, Gal-3 showed significantly higher levels 
of expression in the secretory phase than the proliferative 
phase, regardless of group. Moreover, during both phases, 
Gal-3 expression was significantly down-regulated (secre-
tory stage 0.47 ± 0.02 vs 0.05 ± 0.01, p < 0.05; prolifera-
tive phase 0.26 ± 0.02 vs 0.02 ± 0.01, p < 0.05) in eutopic 
endometrium from endometriosis patients compared to the 
normal endometrium. This result was confirmed at the pro-
tein level by western blot analysis (Fig. 2b).
Gal‑3 expression in epithelial cells and stromal cells 
of endometria
The endometrium becomes receptive to embryonic attach-
ment in the secretory phase of the menstrual cycle; thus, 
we explored whether Gal-3 expression is different in 
EECs and ESCs during this phase. The results of real-
time PCR showed that Gal-3 expression was significantly 
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down-regulated in EECs from the endometriosis group 
compared to the healthy group (0.14 ± 0.06 vs 0.59 ± 0.07, 
p < 0.05) (Fig. 3a). In contrast, there was no significant 
change in Gal-3 expression in ESCs from the control group 
compared to the endometriosis group; however, there was 
a trend of down-regulation of Gal-3 in the endometriosis 
group. We further confirmed these results by western blot 
analysis. As shown in Fig. 3b, a significant down-regulation 
of Gal-3 protein was observed in EECs but not ESCs of 
eutopic endometrial samples from the endometriosis group 
compared to the control group (0.22 ± 0.05 vs 0.58 ± 0.07, 
p < 0.05).
Hormone‑stimulated Gal‑3 expression in endometrial 
epithelial cells
To further investigate the hormone regulation of Gal-3 
expression in EECs, various concentrations of E2 and P4 
were used to co-culture EECs from the control group for 
24 h before mRNA levels of Gal-3 were detected. Our 
results showed that Gal-3 was up-regulated by E2 and 
P4 at all concentrations, reaching peak level at 10−8 and 
10−7 M, respectively (Fig. 4a, b) Thus, concentrations of 
10−8 M of E2 and 10−7 M of P4 were used in the subse-
quent experiments.
Then, the expression of Gal-3 was detected in EECs pre-
treated with 10−8 M E2, 10−7 M P4, or 10−8 M E2 com-
bined with 10−7 M P4 for 24, 48, and 72 h, respectively. In 
the control group, Gal-3 expression was induced by E2 or 
P4 treatment in a time dependent manner (Fig. 5a). Expres-
sion of Gal-3 in the E2P4 group was lower than that in the 
P4 treatment group and higher than that in the E2 treatment 
group. These results suggest Gal-3 induction is more sensi-
tive to P4 than E2 treatment; however, in EECs from the 
eutopic endometria with endometriosis (Fig. 5b), Gal-3 
expression increased slightly after hormone pretreatment 
Fig. 1  Immunohistochemistry analysis of Gal-3 expression. a Nega-
tive control. b Secretory phase endometrium from healthy controls. 
c Secretory phase eutopic endometrium from endometriosis patients 
with infertility. Mouse IgG was used in the negative control (a), while 
Gal-3 antibody was used other analyses (b, c)
Fig. 2  Gal-3 mRNA and protein expression in endometria samples 
from patients and healthy women. a Relative expression levels of 
Gal-3 mRNA in different samples measured by real-time PCR analy-
sis. b Relative expression levels of Gal-3 protein in different samples 
measured by western blot analysis. Expression levels of Gal-3 were 
normalized against those of GAPDH in matched samples. ES endo-
metria of patient with endometriosis in secretory phase, EP endo-
metria of patient with endometriosis in proliferative phase, CS endo-
metria of controls in secretory phase, CP endometria of controls in 
proliferative phase, Control control group, EMT endometriosis group; 
#p < 0.05
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for 24 h, and then decreased time-dependently. Further-
more, compared with the control group, the expression of 
Gal-3 was lower in the endometriosis groups at all time 
points.
Discussion
Endometriosis shows a serious impact on female fertility, 
but the etiology and pathogenesis of endometriosis-related 
infertility are unknown. Thus, it is imperative to identify 
the molecular mechanism of endometriosis to develop an 
effective therapy for endometriosis patients with infertility. 
Several studies have reported that endometriosis is a major 
cause of infertility due to its adverse effect on endometrial 
receptivity to embryonic implantation [26].
Our previous study verified that Gal-3 plays an impor-
tant role in the process of embryonic implantation [25]. 
Intracellular Gal-3 promoted proliferation and adhe-
sion in endometrial cells. Decreased expression of Gal-3 
hindered embryonic adhesion to endometrial epithelial 
cells and delayed proliferation of endometrial stromal cells 
in achieving optimal status to accommodate the invad-
ing embryo, resulting in failed embryonic implantation. 
Secreted Gal-3 inhibited cell proliferation and induced 
apoptosis of endometrial cells [27]. This study shows that 
Gal-3 is expressed in the endometrium of both endometrio-
sis and healthy women, but is reduced significantly in the 
former. This suggests a defect in Gal-3 expression occurs 
in eutopic endometrium from endometriosis patients with 
infertility. Decreased Gal-3 expression in eutopic endo-
metrium from patients with endometriosis may contribute 
to the defective formation of receptive endometrium, thus 
leading to infertility.
Hormonal regulation of cellular function impacts many 
dynamic biological changes occurring during the peri-
implantation stage of the menstrual cycle. Estrogen and pro-
gesterone act coherently at certain time intervals to stimulate 
Fig. 3  Expression of Gal-3 mRNA and protein in epithelial cells and 
stromal cells from secretory phase endometria. a Relative expres-
sion levels of Gal-3 mRNA in EECs and ESCs. b Relative expression 
levels of Gal-3 protein in EECs and ESCs; Ctrl control group, EMT 
endometriosis group, EECs endometrial glandular epithelial cells, 
ESCs endometrial stromal cells; #p < 0.05
Fig. 4  Hormonal regulation of Gal-3 expression by E2 and P4 in 
Endometrial epithelial cells. EECs were treated with E2 (a) (Ctrl, 
10−10–10−6 M) and P4 (b) (Ctrl, 10−9–10−5M) for 24 h, mRNA level 
of Gal-3 was determined by real-time PCR. Gal-3 expression was 
analyzed by real-time PCR and GAPDH was used as an endogenous 
control to normalize for differences. EECs endometrial glandular epi-
thelial cells; #p < 0.05
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the expression of key molecules that regulate endometrial 
receptivity. Our results showed that Gal-3 expression spe-
cifically increased during the secretory phase of the men-
strual cycle in both groups, indicating that Gal-3 may be 
regulated by sex hormones. To confirm this relationship, 
we investigated the effect of hormones on Gal-3 expression 
in both EECs and ESCs. We found that regulation of Gal-3 
expression by E2 and P4 could be detected in EECs but not 
ESCs. This result indicates that Gal-3 may primarily con-
tribute to the dynamic change of EECs during embryonic 
implantation. Then, we explored the physiological dose of 
E2 (10−8 M) and P4 (10−7 M) that maximized Gal-3 expres-
sion in EECs. The results suggested that Gal-3 is regulated 
by sex hormones, which is in agreement with our previous 
study [27]. In the control group, expression of Gal-3 was 
significantly increased when induced by P4 alone, compared 
to E2 alone or E2P4. From these results, we concluded that 
E2, to some degree, antagonized the increased expression of 
Gal-3 by P4 in normal endometrium. In the endometriosis 
group, E2 alone, P4 alone, nor E2P4 could increase Gal-3 
expression to the level of the control group. This indicates 
that there is no induction of Gal-3 expression in response 
to E2 or P4 treatment in the endometriosis group. Previ-
ous reports have shown that progesterone resistance is one 
important factor for endometriosis. Moreover, Gal-3 can 
be detected in the peritoneal fluid of endometriosis patients 
[28–30]; thus, defective progesterone regulation in endome-
triosis women with infertility might account for decreased 
Gal-3 expression in eutopic endometrium.
In summary, we found decreased expression of Gal-3 
in eutopic endometrium from endometriosis, which may 
account for the defective formation of receptive endome-
trium. We further showed that Gal-3 was regulated mainly 
by hormones in EECs. We also suggested that the failure 
of Gal-3 elevation by hormones in EECs from endometri-
osis patients may contribute to progesterone resistance in 
endometriosis-related infertility. Although our study pre-
liminarily indicates that the defective expression of Gal-3 
may contribute to infertility in patients with endometriosis, 
further research is needed to detail the pathways of Gal-3 in 
eutopic endometrium from endometriosis.
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Fig. 5  Defective progesterone regulation in endometrial epithelial 
cells from endometriosis women with infertility. EECs from control 
group (a) and endometriosis group (b) were treated with 10−8 M E2 
with or without 10−7 M P4 and Gal-3 expression was analyzed at 0, 
24, 48, 72 h. Gal-3 expression was analyzed by real-time PCR and 
GAPDH was used as an endogenous control to normalize for differ-
ences. EECs endometrial glandular epithelial cells; #p < 0.05
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